Updates are available Correction dated 2026-05-29

Article History

Received: 29 August 2025

Accepted: 11 March 2026

First Online: 16 April 2026

Change Date: 29 May 2026

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s12282-026-01874-z

Declarations

:

: Dr. Shien reported grants from the Ministry of Health, Labour and Welfare of Japan and from the Japan Agency for Medical Research and Development (AMED) during the conduct of the study, as well as personal fees from Pfizer, Chugai, Lilly, Daiichi Sankyo, MSD, Eizai, AstraZeneca, Taiho, Nihonkayaku, Gilead. Dr. Hara reported the personal fees from Pfizer, Ili Lilly, Daiichi Sankyo, Kyowa Kirin, Chugai, MSD. Dr. Ogawa reported the grants from Japan Agency for Medical Research and Development and Ministry of Health, Labour and Welfare, Japan. Dr. Fukuda reported the grants from National Cancer Center and AstraZeneca, Ono Pharmaceutical Co., Ltd, Chugai Pharmaceutical Co., Ltd, Takeda Pharmaceutical Company Limited and the personal fees from Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., CMIC Co., Ltd. Dr. Iwata reported the grants from Pfizer and Chugai, Daiichi Sankyo, AstraZeneca and personal fees from Daiichi Sankyo, Chugai, AstraZeneca, Lilly, MSD, Pfizer, Taiho, Kyowa Kirin. No other disclosures were reported.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: Informed consent including the secondary use of data was obtained from all individual participants enrolled in JCOG1017.